论文部分内容阅读
目的：观察低强度血管内激光照射（ＩＬＬＬＩ）对恶性肿瘤患者化疗期间免疫功能的影响。方法：观察恶性肿瘤患者化疗期间辅以ＩＬＬＬＩ治疗，与同期未行ＩＬＬＬＩ的对照组患者血清中白细胞介素２受体（ｓＩＬ－２Ｒ）水平的变化。结果：化疗加ＩＬＬＬＩ的实验组化疗后３７．５％患者（９／２４例）ｓＩＬ－２Ｒ水平下降，化疗前后均值分别为５０３×１０３ＩＵ／Ｌ和５５８×１０３ＩＵ／Ｌ。对照组化疗后１００％患者（２４／２４例）ｓＩＬ－２Ｒ水平上升，化疗前后均值分别为４９３×１０３ＩＵ／Ｌ和７４４×１０３ＩＵ／Ｌ。经统计学处理，实验组化疗前后比较ｔ值为１．２３１，Ｐ＞０．０５；对照组化疗前后比较ｔ值为１２．１７７，Ｐ＜０．００１。两组间比较化疗前ｔ值为０．１６１，Ｐ＞０．０５；化疗后ｔ值为２．８３０，Ｐ＜０．０１。结论：恶性肿瘤患者化疗期同时辅以ＩＬＬＬＩ治疗，可不同程度地降低患者ｓＩＬ－２Ｒ的水平，从而缓解化疗药物对恶性肿瘤患者的免疫抑制。
Objective: To observe the effect of low intensity intravascular laser irradiation (ILLLI) on the immune function of patients with malignant tumors during chemotherapy. Methods: To observe the changes of serum interleukin-2 receptor (sIL-2R) levels in patients with malignant tumors supplemented with ILLLI during chemotherapy and in control subjects without ILLLI at the same time. RESULTS: In the chemotherapy group plus ILLLI, 37.5% (9/24) of the patients in the experimental group had decreased sIL-2R levels after chemotherapy. The mean values before and after chemotherapy were 503×103 IU/L and 558×103 IU/L, respectively. In the control group, the level of sIL-2R in 100% patients (24/24 cases) increased after chemotherapy, and the mean values before and after chemotherapy were 493×103 IU/L and 744×103 IU/L, respectively. After statistical analysis, the t value of the experimental group before and after chemotherapy was 1.231, P>0.05; the t value of the control group before and after chemotherapy was 12.177, P<0.001. Between the two groups, the t value before chemotherapy was 0.161, P>0.05; the t value after chemotherapy was 2.830, P<0.01. Conclusion: The treatment of malignant tumor patients with ILLLI at the same time during chemotherapy can reduce the level of sIL-2R in patients with different degrees, so as to alleviate the immunosuppression of chemotherapy drugs in patients with malignant tumors.